Eczema and psoriasis are both chronic inflammatory skin conditions, but they arise from fundamentally different problems. Eczema (atopic dermatitis) is primarily a skin barrier defect that lets the outside world in, while psoriasis is an immune system malfunction that speeds up skin cell production from the inside out. Together, they affect hundreds of millions of people worldwide, and understanding what drives each one helps explain why they look different, feel different, and flare in response to different triggers.
How Eczema Starts: A Broken Skin Barrier
Healthy skin works like a brick wall. Cells are the bricks, and proteins bind them tightly together. One of the most important of these structural proteins is filaggrin, which flattens and strengthens the outermost skin cells into a tough, waterproof barrier. Filaggrin also breaks down into molecules that form the skin’s natural moisturizing factor and help maintain proper skin acidity.
About 20 to 30 percent of people with eczema carry mutations in the gene responsible for filaggrin production, compared with 8 to 10 percent of the general population. Roughly 40 different mutations have been identified so far. When this gene is faulty, the body produces an abnormally short version of the protein that can’t do its job. The result is a barrier full of gaps: too much water escapes (causing chronic dryness), and irritants, allergens, and bacteria slip through easily.
Once the barrier is compromised, the immune system overreacts. Eczema is driven largely by a branch of immunity associated with allergic responses. This pathway ramps up production of signaling molecules that recruit certain white blood cells into the skin, creating the red, itchy, weeping patches characteristic of the disease. This same allergic immune activation explains why eczema frequently travels with asthma, hay fever, and food allergies, a progression doctors call the “atopic march.”
How Psoriasis Starts: An Immune System on Overdrive
Psoriasis is not a barrier problem. It’s a case of the immune system attacking the body’s own skin cells. Specifically, a type of immune cell begins producing inflammatory signals that tell skin cells (keratinocytes) to multiply far faster than normal. Healthy skin cells take about a month to mature and shed. In psoriasis, that cycle compresses to just a few days, and the excess cells pile up into the thick, silvery-scaled plaques that define the condition.
The key inflammatory signals in psoriasis are different from those in eczema. While eczema runs on the allergic side of the immune system, psoriasis is driven by a pathway that normally defends against bacteria and fungi. This pathway produces signals that directly stimulate keratinocyte overgrowth and amplify local inflammation, creating a self-reinforcing loop: immune cells irritate the skin, the irritated skin calls in more immune cells, and the plaques spread or thicken.
Genetics and Family History
Both conditions run in families, but the genetic architecture differs. In eczema, the filaggrin gene on chromosome 1 is the single most important known risk factor. Having one or two copies of a faulty filaggrin gene doesn’t guarantee eczema, but it dramatically increases the odds, especially in combination with environmental exposures.
Psoriasis genetics are more complex and more scattered. Researchers have mapped at least nine major susceptibility regions across different chromosomes. The strongest genetic link is a specific immune system marker called HLA-Cw*0602, found in 100 percent of patients with the guttate (droplet-shaped) form of psoriasis. People who develop psoriasis before age 40 tend to have a stronger genetic component, with more family members affected and more severe disease. A large genetic study found some overlap between psoriasis and eczema susceptibility genes, but the shared genes often operate in opposite directions, reinforcing that these are distinct diseases rather than two versions of the same one.
Environmental Triggers That Cause Flares
Both conditions share some triggers but diverge on others in revealing ways. Weather is the most commonly reported aggravating factor for both, cited by about 75 to 76 percent of patients with either condition. Hot weather is the most frequent culprit for both groups, though cold weather affects a higher proportion of psoriasis patients (31 percent) than eczema patients (22 percent).
The clearest differences show up with stress, sleep, and environmental allergens. Mental stress is over five times more likely to trigger a psoriasis flare than an eczema flare, and inadequate sleep is roughly twice as likely to worsen psoriasis. In the other direction, humidity and dust are significantly more associated with eczema flares. This pattern makes sense given the underlying biology: eczema’s broken barrier lets environmental particles penetrate the skin, while psoriasis responds more to internal signals like stress hormones and disrupted sleep cycles that rev up immune activity.
Food is reported as a trigger by about two-thirds of psoriasis patients and nearly half of eczema patients, with seafood and fermented or pickled foods among the most frequently cited. Chemical exposure affects both groups at similar rates, around 23 percent.
The Role of Skin Bacteria in Eczema
One major driver of eczema that has no real parallel in psoriasis is bacterial colonization. Staphylococcus aureus, a bacterium rarely found in large numbers on healthy skin, is present on the affected skin of nearly 90 percent of eczema patients. Its abundance surges during acute flares.
This isn’t just a bystander effect. The bacterium actively makes eczema worse through several mechanisms. It produces a toxin that triggers mast cells to release histamine and other itch-promoting chemicals, directly fueling the allergic immune response. Another set of toxins damages skin cells in the outer layer of skin, further weakening the already compromised barrier. Perhaps most miserably for patients, Staph aureus produces an enzyme that directly activates the nerve endings responsible for itch, which is why eczema itching can feel so relentless and why scratching only makes things worse by spreading bacteria deeper into broken skin.
How the Two Conditions Look Different
The visual differences between eczema and psoriasis reflect their different causes. Psoriasis produces well-defined, raised plaques with a characteristic silvery scale. The edges are sharp and distinct. Under a microscope, psoriatic skin shows clusters of immune cells that have migrated into the outermost skin layer, a hallmark finding with high diagnostic specificity.
Eczema tends to look less uniform. In children, it typically shows up in the creases of the elbows and behind the knees. In adults, the appearance becomes more variable and harder to pin down, with patches that may be red, oozing, crusted, or thickened depending on how long they’ve been present. Blood work in eczema patients often shows elevated levels of certain white blood cells tied to allergic inflammation, along with higher levels of the antibody associated with allergies, neither of which is typical in psoriasis.
What Each Condition Does Beyond the Skin
Psoriasis carries a wider range of systemic health risks than eczema. The chronic inflammation driving psoriasis doesn’t stay confined to the skin. It spills into the bloodstream and contributes to cardiovascular disease through a process sometimes called the “psoriatic march,” where ongoing inflammation promotes the buildup of arterial plaque independently of traditional risk factors like cholesterol or blood pressure. Psoriasis is also linked to higher rates of metabolic disease, kidney problems, gastrointestinal conditions, and mood disorders. Up to 30 percent of psoriasis patients develop psoriatic arthritis, an inflammatory joint condition that causes pain, swelling, and stiffness.
Eczema’s systemic effects run along a different track. Its strongest associations are with other allergic conditions: asthma, allergic rhinitis, and food allergies. Notably, despite being a chronic inflammatory skin disease, eczema does not appear to carry the same independent cardiovascular risk that psoriasis does. A large systematic review found no comparable effect, suggesting the type of inflammation matters as much as the fact of inflammation itself.